NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology

3 years ago

TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a…

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

3 years ago

Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…

Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States

3 years ago

RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder…

ICU Medical Announces Time of Fourth Quarter 2022 Earnings Conference Call

3 years ago

SAN CLEMENTE, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) --  ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and…

Cerevance Expands Series B Financing with Additional $51 Million 

3 years ago

Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase…

SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering

3 years ago

BILLERICA, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology…

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

3 years ago

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive…

Smart for Life to Hold Shareholder Meeting on March 15, 2023

3 years ago

Shareholder Meeting Follows the Company’s Successful Hearing with the Nasdaq Hearings PanelMIAMI, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Smart for…

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

3 years ago

- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023…

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

3 years ago

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing…